Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-18 pm EDT			5-day change	1st Jan Change
32.48 ^USD	+0.03%		-2.55%	-5.61%

Jun. 11	Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025	CI
Jun. 09	Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03:20 PM

Harmony Biosciences Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM

Published on 01/10/2024 at 20:15

Presenter Speech
Unknown Analyst (Analysts)

Welcome, everyone. I'm [ Sangibita ] with JPMorgan Healthcare, and we are pleased to have with us Dr. Jeffrey Dayno, President and CEO of Harmony

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025	Jun. 11	CI
Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03:20 PM	Jun. 09
Harmony Biosciences, Lupin Settle Lawsuit Over Generic Version of Narcolepsy Drug	Jun. 05	MT
Harmony Biosciences Strengthens Patent Position With Favorable Settlement In ANDA Litigation	Jun. 05	RE
Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating	May. 15	MT
Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated	May. 06	MT
Harmony Biosciences Holdings, Inc., Q1 2025 Earnings Call, May 06, 2025	May. 06
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Earnings Flash (HRMY) Harmony Biosciences Posts Q1 Revenue $184.7M, vs. FactSet Est of $182.3M	May. 06	MT
Earnings Flash (HRMY) Harmony Biosciences Holdings Reports Q1 Adjusted EPS $1.03	May. 06	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2025	May. 06	CI
UBS Adjusts Price Target on Harmony Biosciences to $48 From $55, Maintains Buy Rating	Apr. 28	MT
BofA Cuts Price Target on Harmony Biosciences to $32 From $33	Apr. 21	MT
Harmony Biosciences Holdings, Inc. Appoints Ron Philip to its Board of Directors, Audit Committee and Nominating and Corporate Governance Committee	Apr. 04	CI
Harmony Biosciences Appoints Biotech Leader Ron Philip To Its Board Of Directors	Apr. 03	RE
Harmony Biosciences Names Adam Zaeske As Chief Commercial Officer	Mar. 24	RE
Harmony Biosciences Holdings, Inc. Announces Executive Changes	Mar. 24	CI
Mizuho Adjusts PT on Harmony Biosciences Holdings to $44 From $42, Maintains Outperform Rating	Mar. 17	MT
UBS Adjusts Price Target on Harmony Biosciences to $55 From $56, Keeps Buy Rating	Feb. 27	MT
Harmony Biosciences Holdings, Inc., Q4 2024 Earnings Call, Feb 25, 2025	Feb. 25
Harmony Biosciences' Q4 Adjusted Earnings, Net Product Revenue Rise	Feb. 25	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Feb. 25	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 25	CI
Earnings Flash (HRMY) Harmony Biosciences Posts Q4 Net Product Revenue $201.3M, vs. FactSet Est of $201M	Feb. 25	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2025	Feb. 25	CI